Clinical Trial Update: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the safety and efficacy of Cretostimogene Grenadanorepvec in high-risk non-muscle-invasive bladder cancer. The study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Cretostimogene Grenadanorepvec

Snippet

Sponsor: CG Oncology, Inc. | Conditions: High-Risk Non-Muscle-Invasive Bladder Cancer | Phase 2 | Status: RECRUITING